Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian phase II adaptive randomization by jointly modeling efficacy and toxicity as time-to-event outcomes

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

Bayesian phase I/II adaptively randomized oncology trials with combined drugs

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A Bayesian Phase I/II Trial Design for Immunotherapy

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Bayesian Optimal Phase II Design for Randomized Clinical Trials

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies.

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes